Welcome to our dedicated page for FOXO TECHNOLOGIES news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO TECHNOLOGIES stock.
FOXO Technologies Inc (FOXO) operates at the intersection of epigenetic science and artificial intelligence, delivering innovative solutions for life insurance underwriting and longevity research. This page serves as the definitive source for official company announcements, financial updates, and strategic developments.
Investors and industry observers will find curated coverage of earnings reports, technology partnerships, regulatory milestones, and acquisition activity. Our repository includes press releases related to FOXO Labs' biomarker discoveries and FOXO Life's insurance product innovations, providing insight into how epigenetic data transforms risk assessment models.
Key areas of focus include updates on AI-driven health analytics, strategic expansions into community health initiatives, and advancements in DNA methylation testing methodologies. All content is sourced directly from verified corporate communications to ensure reliability.
Bookmark this page for real-time access to FOXO's evolving role in reshaping insurance through longevity science. Check regularly for critical updates that demonstrate the company's progress in translating epigenetic research into commercial applications.
FOXO Technologies (NYSE American: FOXO) has announced a 1-for-10 reverse stock split of its Class A common stock, effective April 28, 2025, at 4:01pm ET. The stock will begin trading on a split-adjusted basis on April 29, 2025, under the same symbol 'FOXO' but with a new CUSIP number.
The reverse split was approved by stockholders at the Annual Meeting on November 29, 2024, with an authorized ratio range of 1:5 to 1:100. The action aims to ensure compliance with NYSE American's continued listing requirement of maintaining a stock price above $0.10.
For every ten shares held, stockholders will receive one share, with fractional shares rounded up to the next whole number. The split will proportionally affect all outstanding stock options, warrants, and equity incentive plans. Continental Stock Transfer & Trust Company will serve as the exchange agent, managing the conversion process for physical certificates and fractional share adjustments.
FOXO Technologies Inc. (NYSE American: FOXO) has filed its Annual Report on Form 10-K for fiscal year 2024 on April 15, 2025. The company's independent auditors included a going concern explanatory paragraph in their audit opinion, indicating uncertainty about FOXO's ability to continue operations.
CEO Seamus Lagan characterized 2024 as a transition year, highlighting the completion of two strategic acquisitions: Myrtle Recovery Centers, Inc., a behavioral health business, and Rennova Community Health, Inc., which operates rural hospitals in Tennessee. Management expressed optimism about growth prospects from existing operations and potential acquisitions in 2025.
FOXO Technologies Inc. (NYSE American: FOXO) has signed a non-binding agreement to acquire Vector Biosource Inc., an information and biospecimen sourcing provider serving biotechnology and pharmaceutical research industries. Vector projects $800,000 in revenues for 2025 without additional capital.
The acquisition terms include:
- $750,000 in Series D Preferred Stock upfront
- Additional $750,000 in Series D Preferred Stock tied to 2025 revenue milestones
- Future earnout payments in Series D Preferred Stock based on 2026-2027 performance
The deal closing, expected within 45 days, is contingent on definitive agreements, due diligence, $1 million working capital provision, and other conditions. The acquisition aims to leverage Vector's healthcare sector position and growth potential through FOXO's corporate infrastructure and potential subsidiary synergies.
FOXO Technologies (NYSE American: FOXO) has reported positive developments at its behavioral health subsidiary, Myrtle Recovery Centers. The company's substance abuse treatment facility in Oneida, Tennessee has achieved stable operations, maintaining an occupancy rate of 75% or higher since early 2025, occasionally reaching full capacity.
Myrtle has successfully finalized several in-network contracts with major managed care organizations in 2025. The company will participate as a Silver Sponsor in the upcoming ETAADAC Conference in Knoxville, TN (March 19-21, 2025), an event gathering industry leaders to discuss addiction counseling and treatment developments.
FOXO Technologies (NYSE American: FOXO) has executed a non-binding acquisition agreement for two assisted living facilities in Florida for a total consideration of $60 million. The facilities comprise 129 and 137 units respectively, with each facility priced at $30 million including milestone-based payments.
The company aims to complete definitive agreements within 60 days, with closing expected 60-120 days thereafter, subject to due diligence and financing conditions. FOXO is considering funding through a new series of preferred stock listing. The company views these acquisitions as strategic entries into the healthcare sector's recurring revenue model, with milestone payments tied to facility revenue increases.
FOXO Technologies Inc. (NYSE American: FOXO) has provided a shareholder update outlining recent accomplishments and future strategy. The company has transformed from minimal revenues to acquiring businesses with potential for $20M+ annual profitable revenue. They've improved shareholders' equity by over $21M through debt-to-equity restructuring to meet NYSE American listing requirements.
FOXO operates three main businesses: FOXO Labs (epigenetics division with 13,000+ individual dataset), Myrtle Recovery Centers (30-bed behavioral health facility expecting $3-4M annual revenue), and Scott County Community Hospital (Big South Fork Medical Center). The company has converted approximately $6M of additional debt to equity through preferred stock issuance and is actively seeking healthcare sector acquisition opportunities.
Key priorities include growing rural hospital and behavioral health businesses, monetizing the epigenetics division, and potentially pursuing additional healthcare acquisitions. The company plans to update its web presence and complete various work steps within 30-60 days.
FOXO Technologies Inc. (NYSE American: FOXO) has announced its Special Meeting of Shareholders scheduled for January 17, 2025, at 10:30 am EST. The virtual meeting follows the Company's Definitive Proxy Statement filed with the SEC on January 6, 2025. Shareholders of record as of January 3, 2025, will be eligible to vote on the proposed approvals.
Shareholders can vote either online at www.cstproxyvote.com or by attending the virtual meeting at https://www.cstproxy.com/foxotechnologies/2025 using their 12-digit control number. The Board of Directors recommends voting in favor of the Proposals listed on the Proxy Card. CEO Seamus Lagan expressed that the meeting will fulfill obligations from recent acquisition agreements and highlighted the company's transformation in the second half of 2024 as a foundation for building significant shareholder value.
FOXO Technologies (NYSE American: FOXO) has announced a special virtual shareholders meeting scheduled for January 17, 2025, at 10:30 AM EST. The meeting's primary purpose is to seek approval for several proposals, with shareholders of record as of January 3, 2025, eligible to vote.
The main proposal requires shareholder approval for the issuance of Class A Common Stock exceeding 20% of outstanding shares upon conversion of Series A Preferred Stock, and voting terms that may constitute a 'Change of Control' under NYSE American Rules. Additional proposals include potential meeting adjournment if needed to gather more proxies.
CEO Seamus Lagan emphasized that following the meeting, the company plans to focus on growing revenues from existing operations and exploring acquisition opportunities to accelerate growth and increase shareholder value. A Definitive Proxy Statement with detailed information was filed with the SEC on January 6, 2025.
FOXO Technologies Inc. (NYSE American: FOXO) has announced its 2024 Annual General Meeting of Shareholders, scheduled for December 31, 2024, at 9:30 am CST. The meeting will be conducted virtually via live webcast, with shareholders of record as of December 19, 2024, eligible to vote. CEO Seamus Lagan highlighted that FOXO has resolved all NYSE American listing deficiencies and acquired significant revenue-generating businesses. The company plans to hold an additional Special Meeting for other matters requiring shareholder approval. Management expressed optimism about their acquisition and growth strategy for 2025 and beyond.
FOXO Technologies has announced regaining compliance with NYSE American listing requirements by achieving stockholders' equity greater than $4M. This marks a significant turnaround from the company's $17.5M stockholders' deficit reported in September 2024. The improvement was achieved through several key transactions, including:
- Rennova Health's exchange of $21M Senior Secured Note for 21,000 shares of Series A Preferred Stock
- An institutional investor's $1M funding and $2.2M Senior Notes exchange for 2,464 Series A Preferred shares
- Settlement with KR8 AI through 3,000 shares of Series D Preferred Stock
- Conversion of $1M in liabilities to approximately 2M shares of Class A Common Stock
